Drug firm Zydus Cadila today said it has inked an agreement with Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology to identify new drug candidates for treatment of drug resistant infections.
The collaborative research agreement will see scientists from both organisations working together on microbiology and genomics to identify new lead candidate as novel anti-tuberculosis compound, Zydus Cadila said in a filing to the BSE.
Commenting on the development, Zydus Cadila Chairman Pankaj Patel said: "We are committed to support the End TB Strategy."
Disclaimer: No Business Standard Journalist was involved in creation of this content